Karyopharm Therapeutics
KPTI
143 hedge funds and large institutions have $347M invested in Karyopharm Therapeutics in 2021 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 51 increasing their positions, 46 reducing their positions, and 17 closing their positions.
71% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 17
11% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 46
7% more funds holding
Funds holding: 134 → 143 (+9)
4% more capital invested
Capital invested by funds: $334M → $347M (+$12.6M)
0.29% less ownership
Funds ownership: 5.07% → 4.78% (-0.29%)
55% less call options, than puts
Call options by funds: $4.62M | Put options by funds: $10.3M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$10.1M |
| 2 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$3.87M |
| 3 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$3.11M |
| 4 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
+$1.99M |
| 5 |
JP Morgan Chase
New York
|
+$1.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$16.7M |
| 2 |
Morgan Stanley
New York
|
-$5.5M |
| 3 |
Two Sigma Advisers
New York
|
-$4.35M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$3.94M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$3.02M |
KPTI Hedge Fund Activity: Q4 2021 in Review
143 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q4 2021, worth a combined $347M — up 3.8% from $334M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new KPTI positions and 17 closed out — a net gain of 12 holders — while 51 added to existing stakes and 46 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $10.1M. The largest seller was State Street, cutting an estimated $16.7M.
- 143 institutional investors held Karyopharm Therapeutics (KPTI) as of Q4 2021, up from 134 in Q3 2021.
- Funds reported $347M of Karyopharm Therapeutics stock for Q4 2021, up 3.8% quarter-over-quarter.
- 29 funds opened new Karyopharm Therapeutics positions in Q4 2021 and 17 closed out, a net change of +12 holders.
- The largest Karyopharm Therapeutics buyer in Q4 2021 was Millennium Management, an estimated $10.1M added.
- The largest Karyopharm Therapeutics seller in Q4 2021 was State Street, an estimated $16.7M sold.
Based on aggregated 13F filings for Q4 2021.